No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
about
Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectivesCFTR Modulators: Shedding Light on Precision Medicine for Cystic FibrosisThe unfolded protein response affects readthrough of premature termination codonsThe effect of gentamicin-induced readthrough on a novel premature termination codon of CD18 leukocyte adhesion deficiency patients.Targets for cystic fibrosis therapy: proteomic analysis and correction of mutant cystic fibrosis transmembrane conductance regulatorCFTR expression analysis in human nasal epithelial cells by flow cytometry.An international randomized multicenter comparison of nasal potential difference techniques.Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54Suppression of premature termination codons as a therapeutic approach.Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis.Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.Nasal potential difference measurements to assess CFTR ion channel activity.Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.Progress in cystic fibrosis and the CF Therapeutics Development NetworkNovel outcome measures for clinical trials in cystic fibrosisDiscovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.Biomarkers for cystic fibrosis drug development.New drug developments in the management of cystic fibrosis lung disease.U6 promoter-enhanced GlnUAG suppressor tRNA has higher suppression efficacy and can be stably expressed in 293 cells.Restoration of W1282X CFTR activity by enhanced expression.Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model.A multiple reader scoring system for Nasal Potential Difference parameters.Factors influencing readthrough therapy for frequent cystic fibrosis premature termination codons.
P2860
Q28073063-3F69A2BD-1C82-499F-878B-83D1C6169D5BQ28073996-B4BADC2D-929F-4101-B8F2-53945E46CB59Q33623379-4B5C2421-9BA7-47CE-A73E-F8C4B10A413FQ33754791-A039C295-D844-4C3B-82BB-AFEC57FEC943Q34082569-251683AB-370C-47F1-86E6-A228EBE0194EQ34098095-2B251E9E-5E69-4383-B9FB-9978F1396B10Q34184239-006CF67A-DBAC-4085-8481-4E6C516165E6Q34901567-178E4D33-B005-48D7-8F73-19667678BE7BQ35287888-9DB56D55-49F1-44CE-A5FC-4581F96B46EBQ35482151-E6BAAF41-34F7-4AB7-86C3-7044C17782CBQ36203719-C175A109-B983-4DAC-AEFB-31052A61A81CQ36891541-D0E68BAF-23C2-4BE3-8A74-7A35196E14D3Q36968815-CA04923C-1329-498B-B754-D7F5FD0C4477Q36999197-077ED957-B08A-45A5-B89E-E1BA3DB3CE2EQ37140714-8694424A-1404-4643-A41D-95F7A65A0F58Q37164477-E5F33506-1C34-4E01-BEE9-16ED81D4A2C3Q37209004-60B68E77-7D54-4F84-A941-C33B846089A9Q38340406-5C2B330C-9841-4AD0-B990-C8BCD8C75B0BQ38735278-7D72EBEF-76E1-447A-82B3-6CB85914D8F3Q38755600-AF927A71-8EC6-44F2-9362-FD263EB61C38Q38790382-0BB2A6C7-87EC-4AD3-8A49-DD4C375E9772Q39213213-5EF30289-85F9-4583-BC47-BCB668A73563Q40125589-2AB0C9D6-7138-40D4-98D2-BFAF0A19BDC9Q42057135-D66DFD48-82C0-448F-98DC-E545CFF6817AQ46566814-8DF9A050-B35A-4043-9A82-1015DE376D18Q52677951-AADC3C91-2660-447D-93AE-C6C6D6292F6E
P2860
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
No detectable improvements in ...... fibrosis with stop mutations.
@ast
No detectable improvements in ...... fibrosis with stop mutations.
@en
type
label
No detectable improvements in ...... fibrosis with stop mutations.
@ast
No detectable improvements in ...... fibrosis with stop mutations.
@en
prefLabel
No detectable improvements in ...... fibrosis with stop mutations.
@ast
No detectable improvements in ...... fibrosis with stop mutations.
@en
P2093
P2860
P356
P1476
No detectable improvements in ...... fibrosis with stop mutations.
@en
P2093
Bonnie Ramsey
John P Clancy
Michael R Knowles
Moira L Aitken
Nicole Mayer-Hamblett
Pam Zeitlin
Pierre Berclaz
Robert A Oster
Ron Gibson
P2860
P356
10.1165/RCMB.2006-0173OC
P577
2007-03-08T00:00:00Z